Clinical Trial Update: The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety and tolerability of PGV-001-based personalized multi-peptide vaccines in the adjuvant setting for prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PGV-001-based Personalized Multi-peptide Vaccine (PGV-001-based personalized multi-peptide vaccine)

Snippet

Sponsor: Ashutosh Kumar Tewari | Conditions: Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING